Impact of Germline Genetic Testing for Men with Prostate Cancer on Active Surveillance
Abstract
Active surveillance (AS) is the standard-of-care treatment for men with low-risk prostate cancer. Although there is an association between the presence of germline pathogenic variants in certain DNA damage repair (DDR) genes an aggressive prostate cancer, whether presence of these mutations also leads to worse clinical outcomes in men on AS has not been systematically studied. We will conduct a prospective, single arm clinical trial to examine how germline genetic testing in men with prostate cancer on AS affects psychological outcomes and clinical decision making. We will also study the prevalence of germline variants in DDDR genes in this population and compare pathologic outcomes between germline DDR mutation carriers non carriers. We have currently recruited more than half of the planned 600 participants.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2023
- Accession Number
- AD1205943
Entities
People
- Maria I Carlo
Organizations
- Memorial Sloan Kettering Cancer Center